Zobrazeno 1 - 10
of 921
pro vyhledávání: '"Byoung-Chul Cho"'
Autor:
Kumar Prabhash, Daniel Shao Weng Tan, Ross A. Soo, Piyada Sitthideatphaiboon, Yuh Min Chen, Pei Jye Voon, Elisna Syahruddin, Sojung Chu, Reto Huggenberger, Byoung-Chul Cho
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionStage III non-small cell lung cancer (NSCLC) is a heterogeneous disease requiring multimodal treatment approaches. KINDLE-Asia, as part of a real world global study, evaluated treatment patterns and associated survival outcomes in stage I
Externí odkaz:
https://doaj.org/article/0ada5bcfe735499cba04ad948b7874ec
Autor:
Yvonne L. E. Ang, Xiaotian Zhao, Thanyanan Reungwetwattana, Byoung-Chul Cho, Bin-Chi Liao, Rebecca Yeung, Herbert H. Loong, Dong-Wan Kim, James Chih-Hsin Yang, Sun Min Lim, Myung-Ju Ahn, Se-Hoon Lee, Thitiporn Suwatanapongched, Kanchaporn Kongchauy, Qiuxiang Ou, Ruoying Yu, Bee Choo Tai, Boon Cher Goh, Tony S. K. Mok, Ross A. Soo
Publikováno v:
Cancers, Vol 15, Iss 20, p 4999 (2023)
Epidermal growth factor receptor (EGFR) T790M mutations drive resistance in 50% of patients with advanced non-small cell lung cancer (NSCLC) who progress on first/second generation (1G/2G) EGFR tyrosine kinase inhibitors (TKIs) and are sensitive to O
Externí odkaz:
https://doaj.org/article/19298a331a22454798b2aa4975010186
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 7 (2015)
New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-
Externí odkaz:
https://doaj.org/article/575e46fe32a0440396ddc7da10e3d0b7
Autor:
Ki Hyeong Lee1 kihlee@chungbuk.ac.kr, Byoung Chul Cho2, Myung-Ju Ahn3, Yun-Gyoo Lee4, Youngjoo Lee5, Jong-Seok Lee6, Joo-Hang Kim7, Young Joo Min8, Gyeong-Won Lee9, Sung Sook Lee10, Kyung-Hee Lee11, Yoon Ho Ko12, Byoung Yong Shim13, Sang-We Kim14, Sang Won Shin15, Jin-Hyuk Choi16, Dong-Wan Kim17, Eun Kyung Cho18, Keon Uk Park19, Jin-Soo Kim20
Publikováno v:
Cancer Research & Treatment. Jan2024, Vol. 56 Issue 1, p48-60. 13p.
Autor:
Ji Hyun Lee, Seong Gu Heo, Beung‐Chul Ahn, Min Hee Hong, Byoung Chul Cho, Sun Min Lim, Hye Ryun Kim
Publikováno v:
Cancer Medicine, Vol 10, Iss 20, Pp 7012-7020 (2021)
Abstract Background In phase I studies, poziotinib has shown meaningful efficacy against various types of cancers. This phase 2 study aimed to investigate the efficacy and safety of poziotinib in recurrent and/or metastatic head and neck squamous cel
Externí odkaz:
https://doaj.org/article/3977330ad52d4adf994ba1df636f0c79
Autor:
Alexander Drilon, MD, Chao-Hua Chiu, MD, Yun Fan, MD, Byoung Chul Cho, MD, PhD, Shun Lu, MD, PhD, Myung-Ju Ahn, MD, PhD, Matthew G. Krebs, MD, PhD, Stephen V. Liu, MD, Thomas John, MD, Gregory A. Otterson, MD, Daniel S.W. Tan, MD, Tejas Patil, MD, Rafal Dziadziuszko, MD, PhD, Erminia Massarelli, MD, PhD, Takashi Seto, MD, Robert C. Doebele, MD, PhD, Bethany Pitcher, MSc, Nino Kurtsikidze, MD, Sebastian Heinzmann, PhD, Salvatore Siena, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 6, Pp 100332- (2022)
Introduction: Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion–positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials is presented, with substantially longer fo
Externí odkaz:
https://doaj.org/article/46b674c9f39d4db4b8d61e682c4faee9
Autor:
Yeona Cho, Joongyo Lee, Ik Jae Lee, Jun Won Kim, Jong Geol Baek, Dong Min Jung, Byoung Chul Cho, Min Hee Hong, Hye Ryun Kim, Chang Geol Lee, Hong In Yoon
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract We evaluated intracranial failure after hippocampus-avoidance-prophylactic cranial irradiation (HA-PCI) for limited-stage small-cell lung cancer (SCLC). Data of 106 patients who received PCI with 25 Gy were retrospectively reviewed. The pati
Externí odkaz:
https://doaj.org/article/4a709b18b505496c83047c137a9d393f
Autor:
Yun Beom Sang, Joo-Hang Kim, Chang-Gon Kim, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho, Sun Min Lim
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
AXL, along with MER and TYRO3, is a receptor tyrosine kinase from the TAM family. Although AXL itself is not thought to be a potent oncogenic driver, overexpression of AXL is known to trigger tumor cell growth, survival, invasion, metastasis, angioge
Externí odkaz:
https://doaj.org/article/f5d17a5e34b34ab981c3f74270569ed3
Autor:
Sun Min Lim, San-Duk Yang, Sangbin Lim, Seong Gu Heo, Stetson Daniel, Aleksandra Markovets, Rafati Minoo, Kyoung-Ho Pyo, Mi Ran Yun, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Introduction: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that is approved for the use of EGFR -mutant non-small cell lung cancer (NSCLC) patients. In this study, we investigated the acquired resistance mechanisms in NSCLC
Externí odkaz:
https://doaj.org/article/2422d3288270447897efe41264d6b211
Autor:
Byoung Chul Cho1, Dong-Wan Kim2, Ullas Batra3, Keunchil Park4, Sang-We Kim5, Cheng-Ta Yang6, Pei-Jye Voon7, Virote Sriuranpong8, K. Govind Babu9, Khalid Amin10, Yingbo Wang10, Paramita Sen11, Khemaies Slimane10, Sarayut Geater
Publikováno v:
Cancer Research & Treatment. Jan2023, Vol. 55 Issue 1, p83-93. 11p.